Quantcast
Home > Quotes > YMAB

Y-mAbs Therapeutics, Inc. Common Stock (YMAB) Quote & Summary Data

YMAB 
$23.34
*  
0.02
0.09%
Get YMAB Alerts
*Delayed - data as of Mar. 25, 2019  -  Find a broker to begin trading YMAB now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    YMAB Pre-Market
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
32
Today's High / Low
$ 24.12 / $ 22.08
Share Volume
69,381
50 Day Avg. Daily Volume
40,004
Previous Close
$ 23.36
52 Week High / Low
$ 31 / $ 15.17
Market Cap
798,080,164
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
0

Intraday Chart

Shares Traded

Share Volume:
69,381
50 Day Avg. Daily Volume:
40,004

Trading Range

The current last sale of $23.34 is 53.86% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 24.12 $ 31
 Low: $ 22.08 $ 15.17

Company Description (as filed with the SEC)

We are a late­stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody­based therapeutic products for the treatment of cancer. We have a broad and advanced product pipeline, including two pivotal­stage product candidates--naxitamab and omburtamab--which target tumors that express GD2 and B7­H3, respectively. We are developing naxitamab for the treatment of pediatric patients with relapsed or refractory, or R/R, high­risk neuroblastoma, or NB, and radiolabeled omburtamab for the treatment of pediatric patients with central nervous system, or CNS, leptomeningeal metastases, or LM, from NB. NB is a rare and almost exclusively pediatric cancer that develops in the sympathetic nervous system and CNS/LM is a rare and usually fatal complication of NB in which the disease spreads to the membranes, or meninges, surrounding the brain and spinal cord in the CNS.  ... More ...  



Risk Grade

Where does YMAB fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 23.02
Open Date:
Mar. 25, 2019
Close Price:
$ 23.34
Close Date:
Mar. 25, 2019


Consensus Recommendation

Analyst Info